Carna Biosciences,Inc.

4572

TSE PrimePharmaceuticals

¥ -

You can review earnings summary, quarterly trends, full-year progress, and detailed income statement data.

descriptionIncome Statement (PL) Summary

Updated: 2026-08-06FY2026 Q2

Revenue

7.3100M JPY

YoY +27.5%

Operating Income

-9.5100M JPY

YoY +9.4%

Net Income

-21.6100M JPY

YoY -0.7%

EPS

-53.1JPY

YoY +3.9%

Performance Trend

Revenue, operating income and net income trend (last 5 periods)

RevenueOperatingNet Income

20.2億円

9.7億円

-80.5百万円

-11.3億円

-21.8億円

Rev: 20.2億円Op: -5.3億円NI: -5.3億円

Rev: 13.9億円Op: -12.7億円NI: -13.5億円

Rev: 16.3億円Op: -11.2億円NI: -11.5億円

Rev: 6.4億円Op: -20.8億円NI: -21.8億円

Rev: 5.8億円Op: -20.7億円NI: -21.7億円

2021/FY2022/FY2023/FY2024/FY2025/FY

Full-Year Progress

FY2026 Q2

Net Income49.8%

Revenue Progress400M

Revenue Forecast7.200M

Net Income Progress-10.400M

Net Income Forecast-20.900M

Income Statement Details

Unit: JPY

Unlock Long-Term Financial Data

Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.

Standard Plan Premium Plan